Market News & Trends
Triumvira Immunologics Announces First Patient Dosed in Phase 1/2 Cell Therapy Trial
Triumvira Immunologics recently announced the first patient has been dosed in its TACTIC-3 trial, a Phase 1/2 study (NCT05862324) investigating the safety and efficacy of…
Purolite & Repligen Announce Commercial Launch of Novel CH1 Affinity Resin for the Purification of Specialized mAbs
Purolite and Repligen Corporation recently announced the commercial launch of Praesto CH1, a new 70μm (micron) agarose-based affinity resin designed to purify specialized mAbs, such…
MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress
MiNK Therapeutics, Inc. recently announced the publication of results in Nature Communications from a Phase 1/2 study of agenT-797 in patients with moderate-to-severe acute respiratory…
Dyadic Announces Research & Development Collaboration Agreement With Global Biopharmaceutical Company
Dyadic International, Inc. recently announced it has signed a fully funded evaluation agreement including commercial option with an undisclosed leading global biopharmaceutical company to design…
Merck Animal Health to Acquire Elanco’s Aqua Business
Bolsters Merck Animal Health’s position in the aqua industry with comprehensive approach to ensure fish health, welfare and sustainability in aquaculture, conservation and fisheries….
Novo Holdings to Acquire Catalent
Catalent, Inc., a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings, a holding and investment company that is responsible for managing the assets and wealth of the Novo Nordisk Foundation, recently announced they….
BioXcel Therapeutics Announces USPTO’s Allowance of Patent Application for Method of Treating Agitation in Alzheimer’s Disease Using Oromucosal Formulations of Dexmedetomidine
BioXcel Therapeutics, Inc. recently announced the United States Patent and Trademark Office (USPTO) has allowed US Patent Application No. 17/496,470 with claims pertaining to a…
Curia Receives 2024 CDMO Leadership Award
Curia, a leading contract research, development and manufacturing organization, recently announced it has been awarded a 2024 CDMO Leadership Award in the Service category, Small…
Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating its Next-Generation Vaccine Candidates Elicit Mucosal & Systemic Immunogenicity & Reduce Viral Shedding After SARS-CoV-2 Challenge
Vaxart, Inc. recently announced the publication of preclinical non-human primate data demonstrating the potential of its COVID-19 vaccine to protect against multiple SARS-CoV-2 variants of…
Studies Validate Advantages of Administering Drugs to Pets Via IntelGenx’s VetaFilm Platform
IntelGenx Corp. recently announced positive results from a proof-of-concept (POC) study to assess the palatability, owner-perceived acceptability, and ease of repeated administration of IntelGenx’s VetaFilm…
Biovian & 3P Biopharmaceuticals Join Forces to Create 3PBIOVIAN
Biovian and 3P Biopharmaceuticals, two leading biologics Contract Development and Manufacturing Organizations (CDMOs), recently announced their combination to establish a new pan-European leader in their….
Purple Biotech Reaches Recommended Phase 2 Dose for NT219
Purple Biotech Ltd. recently announced it has determined 100mg/kg is the recommended Phase 2 dose (RP2D) for NT219 in combination with cetuximab in the treatment…
Denali Therapeutics Announces Presentations on its Investigational Blood-Brain Barrier-Crossing Enzyme Replacement Therapies
Denali Therapeutics Inc. recently announced upcoming presentations from its Enzyme Transport Vehicle (ETV) development programs, tividenofusp alfa (DNL310) and DNL126 (ETV:SGSH), to be given at…
Ascendia Pharmaceuticals Expanding Injectable Manufacturing Capabilities in 2024
Ascendia Pharmaceuticals is all set to unveil its new injectables manufacturing opportunities with the launch of a state-of-the-art sterile cGMP production facility in March 2024…..
AustinPx Partners With Microsize on KinetiSol Technology, Partnership Strengthens Commercialization Options for AustinPx’s Clients
AustinPx and Microsize recently announced the strategic partnership to accelerate the commercial application of AustinPx’s KinetiSol Technology platform. The collaboration will enable….
Kindeva Drug Delivery Launches New Analytical Services Global Business Unit
Kindeva Drug Delivery recently announced the expansion of its analytical services capabilities — launching a new global business unit offering integrated and stand-alone analytical support to…
BioNTech & DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate
BioNTech SE and Duality Biologics recently announced the US FDA granted Fast Track designation for BNT325/DB-1305 for the treatment of patients with platinum-resistant ovarian epithelial cancer….
Cristalia Products With Nemera’s Reusable Pen Injector Commercialized in Brazil
Cristalia’s human growth hormone will be administered with CRISPEN. Approved by ANVISA1, CRISPEN is part of Nemera’s state-of-the-art pen injector platform PENDURA AD……..
Iterum Therapeutics Announces Positive Topline Results from its Phase 3 Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections
Iterum Therapeutics plc recently announced positive topline results from its REASSURE (REnewed ASsessment of Sulopenem in uUTI caused by Resistant Enterobacterales) Phase 3 clinical trial comparing oral sulopenem (sulopenem etzadroxil…
Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases With University of Florida
Vaxxinity, Inc. recently announced a research collaboration with the University of Florida’s (UF) Center for Translational Research in Neurodegenerative Disease (CTRND) to support its work on…
